BACKGROUND: High plasma aldosterone levels at presentation are correlated to poor outcome after ST elevation acute myocardial infarction (AMI). Whether there is a relationship between aldosterone levels and outcome in a broader spectrum of patients admitted for AMI defined by the new definition based on troponin levels remains unknown. METHODS: Plasma aldosterone, C-reactive protein, and brain natriuretic peptide (BNP) were measured in 471 patients, 24 and 72 hours after admission for AMI defined by the new definition. The primary outcome was the composite of death, resuscitated cardiac arrest, recurrent/extended myocardial infarction, recurrent ischemia, heart failure, and stroke. RESULTS: The highest aldosterone levels quartile at 24 hours was significantly associated with the occurrence of the primary outcome (P < .0001), death (P < .05), heart failure (P < .05), ventricular (P < .0001) and supraventricular arrhythmias (P < .05), and acute renal failure (P < .01) during the in-hospital period, and higher rates of mortality (P < .05) at 1-year follow-up. Independent correlates of the primary outcome at 1 year were age > or =73 (odds ratio [OR] 2.22 [1.38-3.57]), heart failure (OR 6.46 [1.99-20.98]), 24-hour aldosterone > or =103.6 pg.mL(-1) (OR 1.72 [1.07-2.77]), and BNP > or =389 pg.mL(-1) (OR 2.35 [1.44-3.84]) concentrations. The model applied to the 72-hour variables, identified the same correlates. CONCLUSIONS: Using the new definition of AMI, based on troponin levels, regardless of ST-segment elevation and management strategies, high aldosterone concentration is associated with major adverse in-hospital events and is an independent correlate of clinical outcome at 1 year. These findings warrant trials assessing the benefit of early aldosterone blockade in such patients.
BACKGROUND: High plasma aldosterone levels at presentation are correlated to poor outcome after ST elevation acute myocardial infarction (AMI). Whether there is a relationship between aldosterone levels and outcome in a broader spectrum of patients admitted for AMI defined by the new definition based on troponin levels remains unknown. METHODS: Plasma aldosterone, C-reactive protein, and brain natriuretic peptide (BNP) were measured in 471 patients, 24 and 72 hours after admission for AMI defined by the new definition. The primary outcome was the composite of death, resuscitated cardiac arrest, recurrent/extended myocardial infarction, recurrent ischemia, heart failure, and stroke. RESULTS: The highest aldosterone levels quartile at 24 hours was significantly associated with the occurrence of the primary outcome (P < .0001), death (P < .05), heart failure (P < .05), ventricular (P < .0001) and supraventricular arrhythmias (P < .05), and acute renal failure (P < .01) during the in-hospital period, and higher rates of mortality (P < .05) at 1-year follow-up. Independent correlates of the primary outcome at 1 year were age > or =73 (odds ratio [OR] 2.22 [1.38-3.57]), heart failure (OR 6.46 [1.99-20.98]), 24-hour aldosterone > or =103.6 pg.mL(-1) (OR 1.72 [1.07-2.77]), and BNP > or =389 pg.mL(-1) (OR 2.35 [1.44-3.84]) concentrations. The model applied to the 72-hour variables, identified the same correlates. CONCLUSIONS: Using the new definition of AMI, based on troponin levels, regardless of ST-segment elevation and management strategies, high aldosterone concentration is associated with major adverse in-hospital events and is an independent correlate of clinical outcome at 1 year. These findings warrant trials assessing the benefit of early aldosterone blockade in such patients.
Authors: Anthony W Ashton; Thi Y L Le; Celso E Gomez-Sanchez; Marie-Christine Morel-Kopp; Brett McWhinney; Amanda Hudson; Anastasia S Mihailidou Journal: Mol Endocrinol Date: 2015-06-29
Authors: Olivier Moranne; George Bakris; Coraline Fafin; Guillaume Favre; Christian Pradier; Vincent L M Esnault Journal: Clin J Am Soc Nephrol Date: 2013-08-08 Impact factor: 8.237
Authors: Reynaria Pitts; Elise Gunzburger; Christie M Ballantyne; Philip J Barter; David Kallend; Lawrence A Leiter; Eran Leitersdorf; Stephen J Nicholls; Prediman K Shah; Jean-Claude Tardif; Anders G Olsson; John J V McMurray; John Kittelson; Gregory G Schwartz Journal: J Am Heart Assoc Date: 2017-01-10 Impact factor: 5.501
Authors: Anirudh Kumar; Divyang R Patel; Danielle M Brennan; Kathy E Wolski; A Michael Lincoff; Giacomo Ruotolo; Ellen McErlean; Govinda Weerakkody; Jeffrey S Riesmeyer; Stephen J Nicholls; Steven E Nissen; Venu Menon Journal: J Am Heart Assoc Date: 2019-11-22 Impact factor: 5.501